Camfield Peter R, Camfield Carol S
Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
Epilepsia. 2017 Dec;58(12):2048-2052. doi: 10.1111/epi.13916. Epub 2017 Oct 6.
To establish the risk of subsequent intractable epilepsy after ≥2, ≥5, and ≥10 years of remission in childhood-onset epilepsy.
From the Nova Scotia childhood-onset epilepsy population-based cohort patients with all types of epilepsy were selected with ≥20 years follow-up from seizure onset (incidence cases). Children with childhood absence epilepsy were excluded. The rate of subsequent intractable epilepsy was then studied for patients with ≥5 years remission on or off AED treatment and compared with the rate for those with ≥2 and ≥10 years of remission.
Three hundred eighty-eight eligible patients had ≥20 years follow-up (average 27.7 ± (standard deviation) 4 years) until they were an average of 34 ± 6.5 years of age. Overall, 297 (77%) had a period of ≥5 years of seizure freedom (average 21.2 ± 8 years), with 90% of these remissions continuing to the end of follow-up. Seizures recurred in 31 (10%) and were intractable in 7 (2%). For the 332 with a remission of ≥2 years seizure-free, 6.9% subsequently developed intractable epilepsy (p = 0.001). For the 260 with ≥10 years remission, 0.78% subsequently developed intractable epilepsy (p = 0.25 compared with ≥5 years remission).
Even after ≥5 or ≥10 years of seizure freedom, childhood-onset epilepsy may reappear and be intractable. The risk is fortunately small, but for most patients it is not possible to guarantee a permanent remission.
确定儿童期起病的癫痫在缓解≥2年、≥5年和≥10年后发生后续难治性癫痫的风险。
从新斯科舍省儿童期起病的癫痫人群队列中,选择所有类型癫痫且自发作起有≥20年随访的患者(发病病例)。排除儿童失神癫痫患者。然后研究接受或未接受抗癫痫药物(AED)治疗且缓解≥5年的患者发生后续难治性癫痫的比率,并与缓解≥2年和≥10年的患者的比率进行比较。
388名符合条件的患者有≥20年随访(平均27.7±(标准差)4年),直至他们平均年龄为34±6.5岁。总体而言,297名(77%)有≥5年无发作期(平均21.2±8年),其中90%的缓解持续至随访结束。31名(10%)癫痫复发,7名(2%)为难治性癫痫。对于332名无发作缓解≥2年的患者,6.9%随后发展为难治性癫痫(p = 0.001)。对于260名缓解≥10年的患者,0.78%随后发展为难治性癫痫(与缓解≥5年相比,p = 0.25)。
即使在无发作≥5年或≥10年后,儿童期起病的癫痫仍可能复发且为难治性。幸运的是风险较小,但对大多数患者而言,无法保证永久缓解。